Related Links


Rexahn Pharmaceuticals granted European patent for anti-cancer compound, RX-3117

Rexahn Pharmaceuticals announces that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117.

‘In addition to our co-development partnership with Teva, this European patent award further validates the commercial potential of RX-3117,’ said Dr Chang Ahn, Rexahn's Chairman and Chief Executive Officer. ‘The development of RX-3117 strengthens our oncology pipeline, which includes ArchexinTM, currently in Phase II clinical trials.’

RX-3117 is a small-molecule, new chemical entity, nucleoside compound that inhibits DNA methyltransferase, a cyclin-dependent kinase, and DNA synthesis. Potential indications of RX-3117 are solid tumours including colon, lung and pancreatic cancers. In preclinical trials, RX-3117 has demonstrated its ability to overcome cancer drug resistance in cancer cells – in particular, gemcitabine resistance in the human lung cancer cell. The US patent issued for RX-3117 claims composition of matter, synthesis, and methods (2008).

In September 2009, Rexahn – a clinical-stage pharmaceutical company commercializing oncology and central nervous system therapeutics – announced a commercialization and development agreement with Teva for RX-3117. Under the agreement, Rexahn will be eligible to receive additional development, regulatory and sales milestone payments and royalties on net sales worldwide.

Share this article

More services


This article is featured in:
Pharmacology/ Therapeutics


Comment on this article

You must be registered and logged in to leave a comment about this article.